Quantifying ligand bias at seven-transmembrane receptors

Molecular Pharmacology

Volumn 80, Issue 3, 2011, Pages 367-377

  Rajagopal, Sudarshan ^a   Ahn, Seungkirl ^a   Rominger, David H ^b   Gowen MacDonald, William ^b   Lam, Christopher M ^a   DeWire, Scott M ^b   Violin, Jonathan D ^b   Lefkowitz, Robert J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b TREVENA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1A RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ARRESTIN; G PROTEIN COUPLED RECEPTOR; LIGAND;

ARTICLE; BIOLOGY; GENOME; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SIGNAL TRANSDUCTION;

CELL LINE; CYCLIC AMP; HUMANS; INOSITOL PHOSPHATES; LIGANDS; RADIOLIGAND ASSAY; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, CELL SURFACE;

EID: 80051979129     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.072801     Document Type: Article

References (37)

1. Abramson S.N., Martin M.W., Hughes A.R., Harden T.K., Neve K.A., Barrett DA, and Molinoff P.B. (1988) Interaction of beta-adrenergic receptors with the inhibitory guanine nucleotide-binding protein of adenylate cyclase in membranes prepared from cyc-S49 lymphoma cells. Biochem Pharmacol 37:4289-4297. (Pubitemid 18265750)
2. Barnea G., Strapps W., Herrada G., Berman Y., Ong J., Kloss B., Axel R, and Lee K.J. (2008) The genetic design of signaling cascades to record receptor activation. Proc Natl Acad Sci USA 105:64-69.
3. Berg K.A., Maayani S., Goldfarb J., Scaramellini C., Leff P, and Clarke W.P. (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94-104. (Pubitemid 28337591)
4. Black JW and Leff P. (1983) Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220:141-162. (Pubitemid 14217337)
5. Colquhoun D. (1985) Imprecision in presentation of binding studies. Trends Pharmacol Sci 6:197.
6. De Lean A., Stadel JM, and Lefkowitz R.J. (1980) A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J Biol Chem 255:7108-7117. (Pubitemid 11232874)
7. Del Carmine R., Ambrosio C., Sbraccia M., Cotecchia S., Ijzerman AP, and Costa T. (2002) Mutations inducing divergent shifts of constitutive activity reveal different modes of binding among catecholamine analogues to the beta(2)-adrenergic receptor. Br J Pharmacol 135:1715-1722. (Pubitemid 36132706)
8. DeWire S.M., Ahn S., Lefkowitz RJ, and Shenoy S.K. (2007) Beta-arrestins and cell signaling. Annu Rev Physiol 69:483-510.
9. Drake M.T., Violin J.D., Whalen E.J., Wisler J.W., Shenoy SK, and Lefkowitz R.J. (2008) beta-arrestin-biased agonism at the beta2-adrenergic receptor. J Biol Chem 283:5669-5676.
10. Eglen R.M., Bosse R, and Reisine T. (2007) Emerging concepts of guanine nucleotide-binding protein-coupled receptor (GPCR) function and implications for high throughput screening. Assay Drug Dev Technol 5:425-451. (Pubitemid 47067887)
11. Ehlert F.J. (2008) On the analysis of ligand-directed signaling at G protein-coupled receptors. Naunyn Schmiedebergs Arch Pharmacol 377:549-577.
12. Evans B.A., Broxton N., Merlin J., Sato M., Hutchinson D.S., Christopoulos A, and Summers R.J. (2011) Quantification of functional selectivity at the human á(1A)-adrenoceptor. Mol Pharmacol 79:298-307.
13. Fan F., Binkowski B.F., Butler B.L., Stecha P.F., Lewis MK, and Wood K.V. (2008) Novel genetically encoded biosensors using firefly luciferase. ACS Chem Biol 3:346-351.
14. Fargin A., Raymond J.R., Regan J.W., Cotecchia S., Lefkowitz RJ, and Caron M.G. (1989) Effector coupling mechanisms of the cloned 5-HT1A receptor. J Biol Chem 264:14848-14852. (Pubitemid 19237306)
15. Figueroa K.W., Griffin MT, and Ehlert F.J. (2009) Selectivity of agonists for the active state of M1 to M4 muscarinic receptor subtypes. J Pharmacol Exp Ther 328:331-342.
16. Furchgott R.F. (1966) The use of beta-haloaklylamines in the differentiation of the receptors and in the determination of dissociation constants of receptor-agonist complexes, in Advances in Drug Research (Harper NJ and Simmonds AB eds) pp 21-55, Academic Press, New York.
17. Galandrin S and Bouvier M. (2006) Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 70:1575-1584.
18. Gesty-Palmer D., Chen M., Reiter E., Ahn S., Nelson C.D., Wang S., Eckhardt A.E., Cowan C.L., Spurney R.F., Luttrell L.M., et al. (2006) Distinct beta-arrestin- and G proteindependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem 281:10856-10864. (Pubitemid 43855508)
19. Gesty-Palmer D., Flannery P., Yuan L., Corsino L., Spurney R., Lefkowitz RJ, and Luttrell L.M. (2009) A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Science Translational Medicine 1:1ra1.
20. Gregory K.J., Hall N.E., Tobin A.B., Sexton PM, and Christopoulos A. (2010) Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. J Biol Chem 285:7459-7474.
21. Holloway A.C., Qian H., Pipolo L., Ziogas J., Miura S., Karnik S., Southwell B.R., Lew MJ, and Thomas W.G. (2002) Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol Pharmacol 61:768-777. (Pubitemid 34273156)
22. Kenakin T. (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232-238.
23. Kenakin T. (1999) Efficacy in drug receptor theory: Outdated concept or under-valued tool? Trends Pharmacol Sci 20:400-405.
24. Kenakin T. (2007) Functional selectivity through protean and biased agonism: Who steers the ship? Mol Pharmacol 72:1393-1401.
25. Kenakin T and Miller L.J. (2010) Seven transmembrane receptors as shapeshifting proteins: The impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62:265-304.
26. Koole C., Wootten D., Simms J., Valant C., Sridhar R., Woodman O.L., Miller L.J., Summers R.J., Christopoulos A, and Sexton P.M. (2010) Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: Implications for drug screening. Mol Pharmacol 78:456-465.
27. McPherson J., Rivero G., Baptist M., Llorente J., Al-Sabah S., Krasel C., Dewey W.L., Bailey C.P., Rosethorne E.M., Charlton S.J., et al. (2010) μ-Opioid receptors: Correlation of agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol 78:756-766.
28. Molinari P., Vezzi V., Sbraccia M., Grò C., Riitano D., Ambrosio C., Casella I, and Costa T. (2010) Morphine-like opiates selectively antagonize receptor-arrestin interactions. J Biol Chem 285:12522-12535.
29. Rajagopal K., Whalen E.J., Violin J.D., Stiber J.A., Rosenberg P.B., Premont R.T., Coffman T.M., Rockman HA, and Lefkowitz R.J. (2006) Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci USA 103:16284-16289. (Pubitemid 44715188)
30. Rajagopal S., Rajagopal K, and Lefkowitz R.J. (2010) Teaching old receptors new tricks: Biasing seven-transmembrane receptors. Nat Rev Drug Discov 9:373-386.
31. Reiner S., Ambrosio M., Hoffmann C, and Lohse M.J. (2010) Differential signaling of the endogenous agonists at the beta2-adrenergic receptor. J Biol Chem 285:36188-36198.
32. Roth B.L. (2009) Historical overview of the concept of functional selectivity, in Functional Selectivity of G Protein-Coupled Receptor Ligands (Neve K ed) pp 3-7, Springer, New York.
33. Stephenson R.P. (1956) A modification of receptor theory. Br J Pharmacol Chemother 11:379-393.
34. Violin J.D., DeWire S.M., Yamashita D., Rominger D.H., Nguyen L., Schiller K., Whalen E.J., Gowen M, and Lark M.W. (2010) Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 335:572-579.
35. Wei H., Ahn S., Shenoy S.K., Karnik S.S., Hunyady L., Luttrell LM, and Lefkowitz R.J. (2003) Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 100:10782-10787. (Pubitemid 37140105)
36. Whalen E.J., Rajagopal S, and Lefkowitz R.J. (2011) Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol Med 17:126-139.
37. Wisler J.W., DeWire S.M., Whalen E.J., Violin J.D., Drake M.T., Ahn S., Shenoy SK, and Lefkowitz R.J. (2007) A unique mechanism of beta-blocker action: Carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci USA 104:16657-16662. (Pubitemid 350211072)